In/FW
vivo/FW
modulation/NN
of/IN
glucocorticoid/NN
receptor/NN
mRNA/NN
by/IN
inhaled/VBN
fluticasone/NN
propionate/NN
in/IN
bronchial/JJ
mucosa/NN
and/CC
blood/NN
lymphocytes/NNS
in/IN
subjects/NNS
with/IN
mild/JJ
asthma/NN
./.

BACKGROUND/NN
:/:
In/FW
vivo/FW
regulation/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
(/(
GR/NN
)/)
by/IN
glucocorticoids/NNS
provides/VBZ
a/DT
means/NN
of/IN
modulating/VBG
sensitivity/NN
of/IN
targeted/VBN
cells/NNS
./.
=====
OBJECTIVE/NN
:/:
We/PRP
sought/VBD
to/TO
determine/VB
the/DT
in/FW
vivo/FW
modulation/NN
of/IN
GR/NN
mRNA/NN
expression/NN
by/IN
fluticasone/NN
propionate/NN
(/(
FP/NN
)/)
in/IN
subjects/NNS
with/IN
mild/JJ
asthma/NN
./.
=====
METHODS/NNS
:/:
Ten/CD
atopic/JJ
asthmatic/JJ
subjects/NNS
were/VBD
treated/VBN
with/IN
FP/NN
250/CD
microg/NN
twice/RB
daily/RB
for/IN
4/CD
weeks/NNS
./.
=====
Before/IN
and/CC
after/IN
treatment/NN
,/,
the/DT
patients/NNS
underwent/VBD
fiberoptic/JJ
bronchoscopy/NN
with/IN
endobronchial/JJ
biopsy/NN
and/CC
sampling/NN
of/IN
venous/JJ
blood/NN
for/IN
measurements/NNS
of/IN
GR/NN
mRNA/NN
levels/NNS
./.
=====
A/DT
solution/NN
hybridization/NN
assay/NN
was/VBD
used/VBN
for/IN
quantitative/JJ
analysis/NN
of/IN
GR/NN
mRNA/NN
./.
=====
In/IN
addition/NN
,/,
a/DT
24-hour/JJ
urinary/JJ
cortisol/NN
excretion/NN
and/CC
an/DT
adrenocorticotropic/JJ
hormone/NN
test/NN
before/IN
and/CC
after/IN
treatment/NN
with/IN
FP/NN
were/VBD
performed/VBN
./.
=====
RESULTS/NNS
:/:
A/DT
high/JJ
interindividual/JJ
variation/NN
in/IN
GR/NN
mRNA/NN
expression/NN
was/VBD
seen/VBN
./.
=====
However/RB
,/,
we/PRP
detected/VBD
a/DT
significant/JJ
reduction/NN
of/IN
the/DT
GR/NN
mRNA/NN
levels/NNS
in/IN
the/DT
endobronchial/JJ
biopsy/NN
specimens/NNS
after/IN
FP/NN
treatment/NN
(/(
36.6/CD
+/-/CC
23.1/CD
and/CC
25.0/CD
+/-/CC
10.9/CD
amol/NN
GR/NN
mRNA/microg/NN
RNA/NN
,/,
respectively/RB
;/:
P/NN
</JJR
.01/CD
)/)
./.
=====
In/IN
the/DT
peripheral/JJ
blood/NN
lymphocytes/NNS
an/DT
even/RB
more/RBR
striking/JJ
downregulation/NN
of/IN
the/DT
GR/NN
by/IN
its/PRP$
cognate/JJ
ligand/NN
was/VBD
documented/VBN
(/(
30.3/CD
+/-/CC
26.5/CD
and/CC
8.8/CD
+/-/CC
5/CD
amol/NN
GR/NN
mRNA/microg/NN
RNA/NN
,/,
respectively/RB
;/:
P/NN
</JJR
.001/CD
)/)
,/,
possibly/RB
reflecting/VBG
differences/NNS
in/IN
glucocorticoid/NN
sensitivity/NN
between/IN
tissues/NNS
./.
=====
A/DT
small/JJ
but/CC
significant/JJ
reduction/NN
of/IN
the/DT
24-hour/JJ
urinary/JJ
cortisol/NN
excretion/NN
was/VBD
observed/VBN
(/(
233/CD
+/-/CC
109/CD
and/CC
157/CD
+/-/CC
66/CD
nmol/L/NN
,/,
respectively/RB
;/:
P/NN
</JJR
.01/CD
)/)
,/,
whereas/IN
the/DT
feedback/NN
regulation/NN
of/IN
glucocorticoid/NN
synthesis/NN
by/IN
means/NNS
of/IN
the/DT
hypothalamic-pituitary-adrenal/JJ
axis/NN
as/IN
assessed/VBN
by/IN
the/DT
adrenocorticotropic/JJ
hormone/NN
test/NN
remained/VBD
normal/JJ
after/IN
treatment/NN
with/IN
FP/NN
./.
=====
CONCLUSION/NN
:/:
The/DT
results/NNS
in/IN
this/DT
study/NN
confirm/VBP
the/DT
potency/NN
of/IN
the/DT
inhaled/VBN
corticosteroid/NN
FP/NN
and/CC
provide/VBP
evidence/NN
for/IN
a/DT
considerable/JJ
tissue-specific/JJ
interindividual/JJ
variation/NN
in/IN
the/DT
expression/NN
of/IN
the/DT
GR/NN
./.